Focusing on niche areas and unmet medical needs in 5 therapeutic fields
First written in FY2016. 3 of 5 entries say "Restated". Latest entry: FY2026.
1 other company's latest entry also says "Restated".
- FY2026RestatedAnnual report
「In the pharmaceutical business, we will select the optimal modalities from small molecules, nucleic acids and gene therapies, concentrate management resources on diseases and areas with global commercial potential, including hematology and intractable and rare diseases, and promote in-house drug discovery while also leveraging open innovation to complement technologies and accelerate development.」
While maintaining its focus on 4 priority fields, the Company describes the selection of modalities from small molecules, nucleic acids and gene therapies and the concentration of resources on areas with global commercial potential. - FY2023RestatedAnnual report
「In the pharmaceutical business, we will provide high-quality, differentiated medicines that offer hope to patients suffering from disease, primarily targeting disease areas with unmet treatment needs and focusing on 4 priority fields: urology, hematology, intractable and rare diseases, and gynecology.」
The focus on 4 priority fields and disease areas with unmet treatment needs has been reiterated. - FY2021RestatedAnnual report
「In the pharmaceutical business, we will provide high-quality, differentiated medicines that offer hope to patients suffering from disease, primarily targeting disease areas with unmet treatment needs and focusing on 4 priority fields: urology, hematology, intractable and rare diseases, and gynecology.」
The focus on 4 priority fields and disease areas with unmet treatment needs has been reiterated. - FY2019ReframedAnnual report
「In the pharmaceutical business, we will provide high-quality, differentiated medicines that offer hope to patients suffering from disease, primarily targeting disease areas with unmet treatment needs and focusing on 4 priority fields: urology, hematology, intractable and rare diseases, and gynecology.」
The pharmaceutical business strategy identifies 4 priority fields rather than the previous 5. In contrast, descriptions of research and development activities continue to identify 5 fields. - FY2016First statedAnnual report
「In the pharmaceutical business, we will provide high-quality, differentiated medicines that offer hope to patients suffering from disease, primarily targeting niche areas with unmet treatment needs and focusing on 5 priority fields: urology, hematology, intractable and rare diseases, gynecology, and otolaryngology.」
5 priority therapeutic fields have been identified, with niche areas where medical needs remain unmet as the primary targets.